Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,041 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial.
Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, Kasai Y, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Suzuki A, Honda Y, Ogawa Y, Fuyuki A, Imajo K, Higurashi T, Yoneda M, Taguri M, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: ogawa y. Cancers (Basel). 2022 Apr 24;14(9):2112. doi: 10.3390/cancers14092112. Cancers (Basel). 2022. PMID: 35565243 Free PMC article.
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Ozaki A, Kessoku T, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Honda Y, Ogawa Y, Imajo K, Higurashi T, Yoneda M, Taguri M, Yamanaka T, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: ogawa y. Trials. 2020 Jun 1;21(1):453. doi: 10.1186/s13063-020-04385-0. Trials. 2020. PMID: 32487150 Free PMC article.
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T, Imajo K, Kobayashi T, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. Contemp Clin Trials. 2018 Jun;69:40-47. doi: 10.1016/j.cct.2018.04.002. Epub 2018 Apr 5. Contemp Clin Trials. 2018. PMID: 29627620
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Ozaki A, et al. Among authors: ogawa y. Contemp Clin Trials Commun. 2019 Dec 31;17:100516. doi: 10.1016/j.conctc.2019.100516. eCollection 2020 Mar. Contemp Clin Trials Commun. 2019. PMID: 31956725 Free PMC article.
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):996-1007. doi: 10.1016/S2468-1253(20)30216-8. Epub 2020 Aug 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32805205 Clinical Trial.
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Ogawa Y, Imajo K, Saigusa Y, Yamamoto K, Yamanaka T, Usuda H, Wada K, Yoneda M, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. BMJ Open. 2020 Sep 9;10(9):e037961. doi: 10.1136/bmjopen-2020-037961. BMJ Open. 2020. PMID: 32907904 Free PMC article.
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Yoneda M, et al. Among authors: ogawa y. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e001990. doi: 10.1136/bmjdrc-2020-001990. BMJ Open Diabetes Res Care. 2021. PMID: 33593749 Free PMC article. Clinical Trial.
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. Int J Mol Sci. 2021 Jul 29;22(15):8161. doi: 10.3390/ijms22158161. Int J Mol Sci. 2021. PMID: 34360923 Free PMC article. Review.
5,041 results